GA_P advises Ampersand Capital Partners in an investment in Vivebiotech
Gómez-Acebo & Pombo has advised Ampersand Capital Partners, a private equity firm based in Boston (USA) specialized in the life sciences and healthcare sector, in an investment in the Spanish company Vivebiotech, which develops viral vectors for rare diseases and cancer.
Ampersand’s entry will enable the expansion of the Gipuzkoa-based biotech’s lentiviral vector manufacturing capacity and support the execution of its portfolio of pioneering client projects developing innovative cell and gene therapies in vivo and ex vivo.
The team was formed by David González, Diana Linage, Laura Roda and Nicolas Otero, partner, counsel and associates of the corporate team; Mariana Díaz-Moro and Carla Fandiño, partner and associate of the tax team; Irene Fernández-Puyol and Marta Rey, partner and associate of the public team; Lourdes Escassi, Carmen Abad, Laura Calva and Ignacio Luis Campos; counsel and associates of the labor team; Bárbara Sainz de Vicuña and Diego Ibañez; counsel and associate of the IP team; Andrew Ward, partner of the competition team; Isabel Silva, Joaquín Beltrán and Patricia González de Huelbes, associates of the banking team.
